Skip to main content
Aelis Farma logo

Aelis Farma — Investor Relations & Filings

Ticker · AELIS ISIN · FR0014007ZB4 LEI · 8945008D5R6WV7EXRN47 PA Manufacturing
Open in API
Filings indexed 157 across all filing types
Latest filing 2024-01-17 Board/Management Inform…
Country FR France
Listing PA AELIS

About Aelis Farma

https://www.aelisfarma.com

Aelis Farma is a clinical-stage biopharmaceutical company that discovers and develops treatments for brain and central nervous system (CNS) disorders. The company has created a new class of drugs called Signaling Specific inhibitors of the CB1 receptor (CB1-SSi). This proprietary mechanism is designed to selectively inhibit the pathological signaling of the CB1 receptor, which is implicated in various brain diseases, while preserving its normal physiological functions and avoiding adverse effects associated with previous CB1-targeting drugs. The company's lead drug candidate, AEF0117, is in development for the treatment of Cannabis Use Disorder (CUD). Its second candidate, AEF0217, is being investigated for the treatment of cognitive deficits, including those associated with Down syndrome.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Board/Management Information Classification · 100% confidence The document is explicitly titled "Press release" and announces a specific corporate event: the appointment of a new Chief Corporate Development Officer (CDO). This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information. It is not an Annual Report (10-K), an Earnings Release (ER), or a Call Transcript (CT). Since it is a specific announcement about management structure rather than a general regulatory filing fallback (RNS) or a report publication announcement (RPA), the most precise classification is MANG.
2024-01-17 English
Inside Information / Other news releases
Earnings Release Classification · 95% confidence The document is explicitly titled "Press release" and announces a major operational milestone: the completion of patient randomization for a Phase 2b clinical study (AEF0117 for Cannabis Addiction). It provides key updates on timelines, funding (NIH, Indivior agreement), and future steps (Phase 3 readiness). This content structure—a formal announcement of operational progress, often including financial/partnership details, but not the full periodic financial statements (like 10-K or IR)—is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses on operational progress and milestones rather than just quarterly financial figures, and it is a formal press release, it fits best under the 'Earnings Release' category, which often encompasses key operational updates released around reporting periods, or potentially 'Regulatory Filings' (RNS) if it were less specific. Given the focus on clinical trial progress and partnership milestones, ER is the closest fit among the provided options for a significant corporate announcement outside of mandatory periodic reports. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal periodic report (10-K, IR). Q2 2023
2024-01-09 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 93% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and announces a major operational milestone: the finalization of patient recruitment for a Phase 2b clinical study (AEF0117 for cannabis addiction). It provides key highlights, future timelines (Q2 2024 results), financial context (licensing deal with Indivior), and company background. This structure—a formal announcement of operational/clinical progress rather than a full financial report (10-K, IR) or a transcript (CT)—is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses on clinical trial progress and partnership milestones rather than quarterly financial figures, it fits best under the general category for corporate announcements that are not strictly financial results or regulatory filings. However, given the focus on clinical trial progress and the announcement of key milestones, it is a standard type of announcement often released alongside or instead of a formal Earnings Release. Since it is a press release announcing significant operational news, and not a full financial report, 'ER' (Earnings Release) is the closest fit for a major corporate update, although 'RNS' (Regulatory Filings) is a possibility if it were less structured. Given the detailed nature of the announcement (even if not purely financial results), 'ER' is often used for major operational updates in the biotech/pharma sector, or 'RPA' if it were announcing the *release* of a report. Since this *is* the substantive announcement itself, and it contains forward-looking statements and operational updates typical of earnings-related communications, ER is the most appropriate specific code among the choices, though it is not a traditional earnings report. Given the options, and its nature as a major corporate announcement, I will classify it as an Earnings Release (ER) as it communicates key performance indicators (milestones) and outlook, or potentially RNS as a fallback. Given the structure and content, it is a significant corporate announcement, leaning towards ER or RNS. I will select ER as it communicates key operational 'results' (recruitment completion) and outlook, which often accompanies ERs.
2024-01-09 French
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 94% confidence The document is a press release dated January 3, 2024, detailing the semi-annual balance of a liquidity contract (contrat de liquidité) with Invest Securities as of December 29, 2023. It reports on transactions (purchases and sales of shares) during the second half of 2023 and announces a supplementary cash contribution made on January 2, 2024, to maintain liquidity. This type of announcement, which reports on the status and maintenance of a liquidity agreement (often required by market regulators like the AMF in France), is a specific type of corporate action related to share trading and market stability. It is not a full financial report (10-K or IR), an earnings release (ER), or a general regulatory filing (RNS). It specifically details the management of the company's own shares in the market, which aligns closely with the definition of 'Transaction in Own Shares' (POS), as liquidity contracts involve the company or its agent trading the company's stock. However, given the context of reporting on the *contract* status and *supplementary contribution* rather than a direct buyback program execution, it is a specialized disclosure. Since there is no specific code for 'Liquidity Contract Status Report', and it details transactions in the company's own shares, POS is the closest fit, although it could also be argued as a specialized regulatory disclosure falling under RNS if POS is strictly interpreted as direct buyback announcements. Given the detailed transaction tables and the focus on the liquidity mechanism, POS is the most appropriate classification among the provided options, as it directly concerns the company's interaction with its own stock via a formal agreement.
2024-01-03 French
Informations privilégiées / Autres communiqués
Earnings Release Classification · 95% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and details positive non-clinical study results for a drug candidate (AEF0117) that allow it to proceed to Phase 3 clinical trials for Cannabis Use Disorder (CUD). It announces key financial/development milestones (positive toxicology results, advanced development stage, partnership details with Indivior, expected Phase 2b results timeline). This content structure—announcing key operational and scientific progress outside of a formal periodic report (like 10-K or IR)—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate news. Since it focuses on results and progress rather than just financial figures (which would lean towards ER), and it is a formal announcement of corporate development, it fits best under the 'Earnings Release' category, which often encompasses major operational updates released to the market, or potentially 'Regulatory Filings' (RNS) if it were a mandatory filing, but the format strongly suggests a voluntary market communication. Given the options, 'ER' (Earnings Release) is the most appropriate fit for a press release detailing significant clinical/development progress and partnership updates, as these often accompany or substitute for formal earnings announcements in biotech/pharma sectors. It is not a full report (10-K, IR), a presentation (IP), or a voting result (DVA). Q4 2023
2023-11-07 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is explicitly titled "Press release" and announces positive results from non-clinical studies required to enter Phase 3 clinical trials for a drug candidate (AEF0117). It details scientific findings, regulatory milestones achieved, and provides an update on the ongoing Phase 2b study, concluding with financial/partnership details and contact information. This format—a formal announcement of significant operational and scientific progress, often released outside of mandatory quarterly filings—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on operational updates and scientific progress rather than just summarizing period-end financial figures (which would lean towards ER), and it is a formal announcement of material information, it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release if it were tied to a specific reporting period, but the content is primarily scientific/operational news. Given the context of a press release detailing specific, non-financial operational achievements (non-clinical study completion, regulatory clearance for next phase), it is a broad regulatory announcement. However, many companies use press releases for major operational updates that aren't strictly earnings. Since it is a formal announcement of material information that doesn't fit the specific categories like 10-K, IR, or CT, RNS is the most appropriate fallback. If the document were primarily focused on summarizing quarterly financial performance, ER would be chosen. Since it is a detailed update on clinical progress and regulatory steps, RNS is the best fit among the available options for a general regulatory announcement.
2023-11-07 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.